Scientific Breakthrough Canine Lymphoma Cancer (helaas in het Engels)

Hier kun je artikelen/informatie over medische zaken posten en vinden, dat als naslagwerk kan dienen voor de forumleden. Dit is GEEN vragen of discussie-categorie.

Moderator: Charlie Angel

Gesponsord bericht
Berichten: 960
Lid geworden op: Za 31 Jan 2004, 19:14
Locatie: Rucphen

Scientific Breakthrough Canine Lymphoma Cancer (helaas in het Engels)

Berichtdoor Elvira » Ma 27 Nov 2006, 17:05

Subject: Scientific Breakthrough in the Screening & Treatment of
Canine Lymphoma Cancer is a World First

News Release
Tuesday 21 November 2006, 18:21 GMT Tuesday 21 November 2006
Petscreen Limited

Scientific Breakthrough in the Screening & Treatment of Canine
Lymphoma Cancer is a World First

NOTTINGHAM, England, November 21 /PRNewswire/ --

- One of the Most Prolific Cancer Killers in Dogs can now be
Routinely Screened for With a Simple Blood Test

Canine lymphoma is one of the most prolific cancers in the dog
population. It accounts for more than 20% of all cancers and in
certain high risk breeds this figure could be considerably higher.
Now a pioneering British bioscience company, PetScreen Limited ( has announced an innovative screening and
treatment optimisation programme which is the first of its kind to be
made commercially available.

The screen is inexpensive, minimally invasive and relies on a small
blood sample which can be taken by any vet, and then conveniently
shipped directly to PetScreen's laboratories in Nottingham from
anywhere in the world using a global logistics partnership with FedEx.

PetScreen has developed the screen based on proteomic technology
which has emerged from the sequencing of both the human and canine
genomes. It facilitates regular, routine screening which enables
cancer to be detected at a much earlier stage when, as in humans,
treatment has the best chance of success. The problems associated
with the late detection of cancer are well understood, and whilst
proteomic screening is at a comparatively early stage in humans, an
ovarian cancer screen is expected to be announced in the United
States next year... the work that PetScreen is undertaking in the
canine world will have a significant impact for both four and two legs.

The scientific team, led by Dr Shahid Mian, has uniquely developed
advanced biomarker technology for companion animals, specifically
canine at the moment, but a feline lymphoma screen is planned for
next year. Additional cancer screens for other major canine tumours
will also be announced in 2007.

By looking for a "protein fingerprint" in the blood sample, the
PetScreen proteomic screen enables very accurate and sensitive
detection of the tumour, but just as importantly, indicates that the
dog is free of lymphoma. The screen should therefore be regarded as
part of an overall wellness programme for all breeds and provides
owners with peace of mind ... particularly high risk breeds, which
include both golden and flat-coated retrievers, boxers, rottweilers,
German shepherds, spaniels and many breeds of mountain dogs. Ideally
a mature pup should be screened at twelve months and then annually.
For high risk breeds and dogs from middle age onwards, bi-annual
screening should be considered, since six months in the life of a dog
is equivalent to approximately three years in human terms. Any dog
which may have been treated for lymphoma should be screened
bi-annually to monitor for recurrence.

One in four dogs will develop cancer in their lifetime. Therefore, to
complement the screening technology, PetScreen has developed a novel
treatment optimisation programme which helps vets select the most
appropriate chemotherapy treatment for each patient.

PetScreen recognise the impact of this devastating disease on dogs
and owners alike. The company was co-founded by business partners who
share a passion for dogs. The company's Chairman Professor Graeme
Radcliffe, had lost three young dogs to cancer over a five year
period. His determination to do something positive led to a chance
meeting with Chief Executive, Dr Kevin Slater, an entrepreneurial
bioscientist who had worked on human biomarker programmes. The
meeting led to the partnership which founded Petscreen ... and the
development of this innovative screening and treatment programme.

For further information, background and digitised photography please
visit the press centre of our website: or contact
Dr Kevin Slater, Chief Executive or Dr Shahid Mian on the telephone
numbers below.

PetScreen Limited Freephone: (UK only) 0800-028-4811

Distributed by PR Newswire on behalf of Petscreen Limited

Terug naar “Bibliotheek Medisch”

Wie is er online

Gebruikers op dit forum: Geen geregistreerde gebruikers en 0 gasten